CoChat

Macimorelin as a Diagnostic Test for Adult GH Deficiency

Garcia, Jose M, Biller, Beverly M K, Korbonits, Márta, Popovic, Vera, Luger, Anton, Strasburger, Christian J, Chanson, Philippe, Medic-Stojanoska, Milica, Schopohl, Jochen, Zakrzewska, Anna, Pekic, Sandra, Bolanowski, Marek, Swerdloff, Ronald, Wang, Christina, Blevins, Thomas, Marcelli, Marco, Ammer, Nicola, Sachse, Richard, Yuen, Kevin C J · 2018 · The Journal of Clinical Endocrinology & Metabolism
Cited by 105

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

Purpose: The diagnosis of adult GH deficiency (AGHD) is challenging and often requires confirmation with a GH stimulation test (GHST). The insulin tolerance test (ITT) is considered the reference standard GHST but is labor intensive, can cause severe hypoglycemia, and is contraindicated for certain patients. Macimorelin, an orally active GH secretagogue, could be used to diagnose AGHD by measuring stimulated GH levels after an oral dose. Materials and Methods: The present multicenter, open-label, randomized, two-way crossover trial was designed to validate the efficacy and safety of single-dose oral macimorelin for AGHD diagnosis compared with the ITT. Subjects with high (n = 38), intermediate (n = 37), and low (n = 39) likelihood for AGHD and healthy, matched controls (n = 25) were included in the efficacy analysis. Results: After the first test, 99% of macimorelin tests and 82% of ITTs were evaluable. Using GH cutoff levels of 2.8 ng/mL for macimorelin and 5.1 ng/mL for ITTs, the negative agreement was 95.38% (95% CI, 87% to 99%), the positive agreement was 74.32% (95% CI, 63% to 84%), sensitivity was 87%, and specificity was 96%. On retesting, the reproducibility was 97% for macimorelin (n = 33). In post hoc analyses, a GH cutoff of 5.1 ng/mL for both tests resulted in 94% (95% CI, 85% to 98%) negative agreement, 82% (95% CI, 72% to 90%) positive agreement, 92% sensitivity, and 96% specificity. No serious adverse events were reported for macimorelin. Conclusions: Oral macimorelin is a simple, well-tolerated, reproducible, and safe diagnostic test for AGHD with accuracy comparable to that of the ITT. A GH cutoff of 5.1 ng/mL for the macimorelin test provides an excellent balance between sensitivity and specificity.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1210/jc.2018-00665

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 26

  1. Woodhouse, 1999, Measures of submaximal aerobic performance evaluate and predict functional response to growth hormone (GH) treatment in GH-deficient adults, J Clin Endocrinol Metab, 84, 4570
  2. Biller, 2000, Withdrawal of long-term physiological growth hormone (GH) administration: differential effects on bone density and body composition in men with adult-onset GH deficiency, J Clin Endocrinol Metab, 85, 970
  3. Attanasio, 2002, Body composition, IGF-I and IGFBP-3 concentrations as outcome measures in severely GH-deficient (GHD) patients after childhood GH treatment: a comparison with adult onset GHD patients, J Clin Endocrinol Metab, 87, 3368, 10.1210/jcem.87.7.8593 · doi:10.1210/jcem.87.7.8593 · Paper page
  4. Hoffman, 2004, Growth hormone (GH) replacement therapy in adult-onset GH deficiency: effects on body composition in men and women in a double-blind, randomized, placebo-controlled trial, J Clin Endocrinol Metab, 89, 2048, 10.1210/jc.2003-030346 · DOI · Paper page
  5. Bollerslev, 2006, Positive effects of a physiological dose of GH on markers of atherogenesis: a placebo-controlled study in patients with adult-onset GH deficiency, Eur J Endocrinol, 154, 537, 10.1530/eje.1.02125 · DOI · Paper page
  6. Yuen KC . Glucagon stimulation testing in assessing for adult growth hormone deficiency: current status and future perspectives. ISRN Endocrinol. 2011; 2011:608056. · DOI · Paper page
  7. Yuen, 2013, Clinical characteristics, timing of peak responses and safety aspects of two dosing regimens of the glucagon stimulation test in evaluating growth hormone and cortisol secretion in adults, Pituitary, 16, 220, 10.1007/s11102-012-0407-7 · DOI
  8. Gnanapavan, 2002, The tissue distribution of the mRNA of ghrelin and subtypes of its receptor, GHS-R, in humans, J Clin Endocrinol Metab, 87, 2988, 10.1210/jcem.87.6.8739 · DOI · Paper page
  9. Piccoli, 2007, Pharmacokinetics and pharmacodynamic effects of an oral ghrelin agonist in healthy subjects, J Clin Endocrinol Metab, 92, 1814, 10.1210/jc.2006-2160 · DOI · Paper page
  10. Garcia, 2013, Macimorelin (AEZS-130)-stimulated growth hormone (GH) test: validation of a novel oral stimulation test for the diagnosis of adult GH deficiency, J Clin Endocrinol Metab, 98, 2422, 10.1210/jc.2013-1157 · DOI · Paper page
  11. Manolopoulou, 2012, Automated 22-kD growth hormone-specific assay without interference from Pegvisomant, Clin Chem, 58, 1446, 10.1373/clinchem.2012.188128 · DOI · Paper page
  12. Bidlingmaier, 2014, Reference intervals for insulin-like growth factor-1 (IGF-I) from birth to senescence: results from a multicenter study using a new automated chemiluminescence IGF-I immunoassay conforming to recent international recommendations, J Clin Endocrinol Metab, 99, 1712, 10.1210/jc.2013-3059 · DOI · Paper page
  13. Clemmons, 2011, Consensus statement on the standardization and evaluation of growth hormone and insulin-like growth factor assays, Clin Chem, 57, 555, 10.1373/clinchem.2010.150631 · DOI · Paper page
  14. Tobi, 2005, Small proportions: what to report for confidence intervals, Pharmacoepidemiol Drug Saf, 14, 239, 10.1002/pds.1081 · DOI · Paper page
  15. Indik, 2006, Bazett and Fridericia QT correction formulas interfere with measurement of drug-induced changes in QT interval, Heart Rhythm, 3, 1003, 10.1016/j.hrthm.2006.05.023 · DOI · Paper page
  16. Yuen, 2009, Clinical review: is lack of recombinant growth hormone (GH)-releasing hormone in the United States a setback or time to consider glucagon testing for adult GH deficiency, J Clin Endocrinol Metab, 94, 2702, 10.1210/jc.2009-0299 · DOI · Paper page
  17. Gasco, 2012, Acylated ghrelin as a provocative test for the diagnosis of GH deficiency in adults, Eur J Endocrinol, 168, 23, 10.1530/EJE-12-0584 · DOI
  18. Korbonits, 1999, Hexarelin as a test of pituitary reserve in patients with pituitary disease, Clin Endocrinol (Oxf), 51, 369, 10.1046/j.1365-2265.1999.00828.x · DOI
  19. Petersenn, 2002, Diagnosis of growth hormone deficiency in adults by testing with GHRP-6 alone or in combination with GHRH: comparison with the insulin tolerance test, Eur J Endocrinol, 146, 667, 10.1530/eje.0.1460667 · DOI
  20. Broglio, 2002, EP1572: a novel peptido-mimetic GH secretagogue with potent and selective GH-releasing activity in man, J Endocrinol Invest, 25, RC26, 10.1007/BF03345096 · DOI
  21. Chanson, 2010, Comparative validation of the growth hormone-releasing hormone and arginine test for the diagnosis of adult growth hormone deficiency using a growth hormone assay conforming to recent international recommendations, J Clin Endocrinol Metab, 95, 3684, 10.1210/jc.2010-0295 · DOI · Paper page
  22. Hoeck, 1999, Differences in reproducibility and peak growth hormone responses to repeated testing with various stimulators in healthy adults, Growth Horm IGF Res, 9, 18, 10.1054/ghir.1998.0085 · DOI
  23. Lissett, 1999, How many tests are required to diagnose growth hormone (GH) deficiency in adults, Clin Endocrinol (Oxf), 51, 551, 10.1046/j.1365-2265.1999.00836.x · DOI · Paper page
  24. Hartman, 2002, Which patients do not require a GH stimulation test for the diagnosis of adult GH deficiency, J Clin Endocrinol Metab, 87, 477, 10.1210/jcem.87.2.8216 · DOI · Paper page
  25. Marcum, 2012, FDA drug safety communications: a narrative review and clinical considerations for older adults, Am J Geriatr Pharmacother, 10, 264, 10.1016/j.amjopharm.2012.05.002 · DOI · Paper page
  26. Kacheva, 2017, QT prolongation caused by insulin-induced hypoglycaemia—an interventional study in 119 individuals, Diabetes Res Clin Pract, 123, 165, 10.1016/j.diabres.2016.11.021 · DOI

Cited by

See all 105

Metadata

Authors
Garcia, J. M., Biller, B. M. K., Korbonits, M., Popovic, V., Luger, A., Strasburger, C. J., Chanson, P., Medic-Stojanoska, M., Schopohl, J., Zakrzewska, A., Pekic, S., Bolanowski, M., Swerdloff, R., Wang, C., Blevins, T., Marcelli, M., Ammer, N., Sachse, R., & Yuen, K. C. J.
Affiliations
  • Geriatric Research Education and Clinical Center, Veterans Affairs Puget Sound Health Care System, University of Washington and SIBCR, Seattle, Washington
  • Massachusetts General Hospital, Boston, Massachusetts
  • Barts and the London School of Medicine, Queen Mary University of London, London, United Kingdom
  • University of Belgrade Faculty of Medicine, Belgrade, Serbia
  • Vienna General Hospital – Medical University Campus, Vienna, Austria
  • Charité – Universitatsmedizin, Berlin, Germany
  • Service d’Endocrinologie et des Maladies de la Reproduction, Centre de Référence des Maladies Rares de l’Hypophyse, Assistance Publique-Hôpitaux de Paris, Hôpital de Bicêtre, Le Kremlin Bicêtre, France
  • University of Novi Sad, Faculty of Medicine, Clinical Center of Vojvodina, Novi Sad, Serbia
  • Medizinische Klinik IV, Ludwig Maximilian University of Munich, Munich, Germany
  • Angelius Provita Medical Center, Katowice, Poland
  • WroMedica, Wrocław, Poland
  • Los Angeles Biomedical Research Institute, Harbor-UCLA Medical Center, Torrance, California
  • Texas Diabetes and Endocrinology, Austin, Texas
  • Baylor College of Medicine and Michael E. DeBakey Veterans Affairs Medical Center, Houston, Texas
  • Aeterna Zentaris GmbH, Frankfurt, Germany
  • Swedish Neuroscience Institute, Seattle, Washington
Venue
The Journal of Clinical Endocrinology & Metabolism
Published
2018-05-31
Volume
103
Issue
8
Pages
3083-3093
ISSN
  • 0021-972X
  • 1945-7197
Cited by
105
References
5
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.